Clinical Trial Update: Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD

View source ↗

Summary

This clinical trial update describes a long-term follow-up study of RGX-314 gene therapy delivered in the suprachoroidal space for neovascular age-related macul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• RGX-314

Snippet

Sponsor: AbbVie | Conditions: Neovascular Age-Related Macular Degeneration (nAMD), Gene Therapy | Status: ENROLLING_BY_INVITATION